Leading Critical
Care Solutions

Tenax Therapeutics is focused on identifying, developing and commercializing products for the critical care market.

In the U.S. alone, more than five million hospitalized patients are treated in an intensive care setting annually according to the Society of Critical Medicine.

Enrollment Update:

trial-logo-levocts

820

  as of September 20, 2016

Focus on Critical Care

Given the high mortality, morbidity, and costs associated with the treatment of many intensive care patients, we believe that there is a substantial opportunity to add value for patients, physicians, hospitals, and ultimately shareholders.